Tarsus Pharmaceuticals (TARS) Cash from Operations (2019 - 2026)

Tarsus Pharmaceuticals' Cash from Operations history runs 8 years deep, the most recent figure standing at 24652000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 19.37% year-over-year to 24652000.0 in Q1 2026; TTM through Mar 2026 was 16452000.0, a 75.03% increase from a year earlier, with the FY2025 full-year figure at 12451000.0, up 85.0% from the prior year.
• Cash from Operations retreated to 24652000.0 in Q1 2026 per TARS's latest filing, from 19330000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 19330000.0 in Q4 2025 and bottomed at 39335000.0 in Q4 2023.
• The 5-year median for Cash from Operations is 20651000.0 (2025), against an average of 16861941.18.
• Across the five-year window, Cash from Operations sank 459.43% in 2023 and soared 311.01% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 10874000.0 in 2022, then plunged by 261.73% to 39335000.0 in 2023, then soared by 43.61% to 22182000.0 in 2024, then surged by 187.14% to 19330000.0 in 2025, then tumbled by 227.53% to 24652000.0 in 2026.
• Per Business Quant, the three latest TARS Cash from Operations figures stand at 24652000.0 (Q1 2026), 19330000.0 (Q4 2025), and 18257000.0 (Q3 2025).